Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...

Global Implantable Infusion Pump Market Set for Steady Growth from 2022 to 2032, Driven by Chronic Disease Management and Technological Advances.

The autoinjector offers potential pain relief and is designed for self-administration, eliminating the need for refrigeration ...

Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...

Patients in the US with newly diagnosed GCA face excessive delays to initiating subcutaneous TCZ, as well high out-of-pocket costs.

TG Therapeutics reported strong revenue growth, driven by Briumvi's success in MS treatment. Find out why I upgraded my ...

The results showed comparable efficacy between the two formulations, with objective response rates of 24.2% vs 18.2% for subcutaneous and intravenous nivolumab, respectively. Safety profiles were ...

Halozyme is best known for its Enhanze subcutaneous delivery technology ... the top-selling cancer immunotherapy when the original intravenous infusion formulation falls off the patent cliff ...